3,000,000 buy order at 16, page-17

Indeed, strange days are upon us: there's been a couple of explosions in the biotech space over the last week or so: ADO was a minnow who earned a solid revenue stream from a clinical tool - boomed 15 fold in a couple of days before settling to a mere 10 fold, and today VLA tripled on very promising results in a Phase-I melanoma trial.

Believe it or not folks but we are standing in the middle of a gold-rush frenzy that our forebears in Bathurst, Ballarat and Kalgoorlie would be familiar with.

Tana was sceptical that good Phase-III results would boost the Avexa SP. The reasoning is sound but somehow I think the game has changed.

Goes both ways of course - if Phase-III were to disappoint, then Avexa would become a legend in the space of a lunchtime for the rapidity of its fall.

One thing I think we can count on is that Avexa will call a trading halt before releasing anything dramatic - that didn't happen with either ADO or VLA !! Just 'price sentisitive announcements' !!

And people say Avexa's board is a bit sloppy!

Regards,
P.